Dark

DARE
Dare Bioscience, Inc. Common Stock
stock NASDAQ

Market Open

Jul 22, 2026 11:34:45 AM EDT

1.25USD+0.400%(0.00)153,266

1.25Bid 1.26Ask 0.01Spread

Pre-market

Jul 22, 2026 9:25:30 AM EDT

1.26USD+0.800%(+0.01)8,411

After-hours

Jul 21, 2026 4:03:30 PM EDT

1.25USD+0.402%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 4, 2022

08:00AM EST Dar Bioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright BIOCONNECT 2022 Conference being held virtually January 10 13, 2022. GlobeNewswire Inc

Dec 7, 2021

04:22PM EST Dare Biosciences Shares To Resume Trade At 4:45 p.m. EST Benzinga

04:16PM EST Dar Announces FDA Approval Of XACIATO Vaginal Gel As A Treatment For Bacterial Vaginosis Benzinga

04:15PM EST Dar Announces FDA Approval of GlobeNewswire Inc

12:29PM EST Traders Circulate FDA AccessData.gov Listing Showing Dare's Clindamycin Phosphate Vaginal Gel FDA Approved Benzinga

11:21AM EST REMINDER: Dare Biosciences Scheduled For Priority Review Result For Co.'s New Drug Application For Its Bacterial Vaginosis Drug Candidate Tuesday, Dec. 7 Benzinga

11:16AM EST Dare Biosciences Shares Halted, News Pending Benzinga

08:26AM EST The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Dar Benzinga

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Dec 2, 2021

12:02PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 10, 2021

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

08:23AM EST Dare Bioscience Q3 EPS $(0.18) Misses $(0.13) Estimate Benzinga

08:00AM EST Significant progress on several key clinical and corporate initiatives with the portfolio during the third quarter, including DARE-BV1 NDA acceptance and Ovaprene NIH CRADA for the pivotal Phase 3 GlobeNewswire Inc

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 9, 2021

08:01AM EST Dar Bioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference being held November 15-17, 2021. GlobeNewswire Inc

Nov 3, 2021

08:00AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that it will host a conference call and live webcast at4:30 p.m. Eastern Timeon Wednesday, November 10, 2021, to review its financial results for the quarter ended September 30, 2021 and to provide a Company update. GlobeNewswire Inc

Oct 6, 2021

08:52AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced its participation in DTC Perspectives Xpectives.Health Summit being held in Boston, MA from October 12 14, 2021, at The Westin Copley Place. GlobeNewswire Inc

Sep 27, 2021

08:16AM EDT Dar Bioscience Announces $309,614 NIH Grant Award To Support Development Of DARE-LARC1 Benzinga

08:00AM EDT Dar Bioscience Announces NIH Grant Award to Support GlobeNewswire Inc

Sep 23, 2021

08:05AM EDT Dare Bioscience Reports Initiation Of Phase 1/2 Study Of DARE-VVA1 For Treatment Of Vulvar, Vaginal Atrophy Benzinga

08:00AM EDT Investigational therapy for women who cannot, or should not, take supplemental estrogen GlobeNewswire Inc

Sep 22, 2021

08:00AM EDT Dar Bioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Virtual Global Healthcare Conference being hosted by the Cantor Fitzgerald Healthcare team September 27 30, 2021. GlobeNewswire Inc

Sep 8, 2021

08:00AM EDT Dar Bioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13 15, 2021. GlobeNewswire Inc

Sep 7, 2021

08:00AM EDT The discussion, Womens Health Case Study: Optimizing Study Enrollment During the COVID-19 Pandemic, will review theDARE-BVFREE Phase 3 study that was successfully initiated and completed during 2020 GlobeNewswire Inc

Sep 1, 2021

08:00AM EDT Presentation will highlight the positive topline results from the Phase 1 clinical trial of DARE-HRT1 GlobeNewswire Inc

Aug 12, 2021

08:20AM EDT Dare Bioscience Q2 EPS $(0.18) Misses $(0.16) Estimate Benzinga

08:15AM EDT Dar Bioscience Q2 Loss Per Share $0.18 Vs Loss $0.21 Last Year RTTNews

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

08:00AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today reported financial results for the quarter ended June 30, 2021 and provided a company update. GlobeNewswire Inc

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

08:01AM EDT Dar Bioscience Announces FDA Acceptance And Priority Review Of New Drug Application For DARE-BV1 For Treatment Of Bacterial Vaginosis Benzinga

08:00AM EDT -- Six-month priority review granted for DARE-BV1 with PDUFA target action date set for December 7, 2021. -- NDA supported by positive data from the DARE-BVFREE Phase 3 study, which demonstrated clinical cure rates of 70-81% from a single vaginal dose of DARE-BV1. -- Ongoing strategic discussions underway to support a robust market introduction of the product in 2022, if approved. GlobeNewswire Inc

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 26, 2021

08:00AM EDT Presentation will highlight the positive topline results from the DARE-BVFREE Phase 3 randomized, double-blinded, placebo-controlled clinical trial evaluating Dars product candidate DARE-BV1 in women diagnosed with bacterial vaginosis GlobeNewswire Inc

Jul 12, 2021

05:59AM EDT Dar Announces Collaborative Research Agreement For The Pivotal Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Contraceptive Benzinga

05:45AM EDT Funding and Clinical Operations Support will be Provided by the National Institutes of Healths Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Under the CRADA GlobeNewswire Inc

Jul 7, 2021

02:52PM EDT Mid-Afternoon Market Update: Dow Rises 70 Points; IDEAYA Biosciences Shares Slide Benzinga

12:18PM EDT Mid-Day Market Update: Crude Oil Down 2.5%; Opiant Pharmaceuticals Shares Jump Benzinga

11:38AM EDT Why Dare Bioscience (DARE) Stock Trading Higher On Wednesday? Benzinga

06:15AM EDT Dare Bioscience On June 30, Entered Into Agreement With Bill & Melinda Gates Foundation & Were Awarded New Grant Of Up To $48.95M To Support Development Of DARE-LARC1 Benzinga

Jun 30, 2021

11:20AM EDT UPDATE: Roth Capital On Dar Bioscience: Firm Cites Phase 1 DARE-HRT1 Data For Menopausal Symptoms As 'Highly Validating And De-Risking For DARE-FRT1' Resulting In Clinically Meaningful Improvements In Vasomotor Menopausal Symptoms. Benzinga

11:16AM EDT Roth Capital Maintains Buy Rating On Dar Bioscience, Increases Price Target From $9 To $11. Benzinga

Jun 28, 2021

09:14AM EDT Dar Bioscience's DARE-HRT1 Shows Potential As Monthly Therapy For Vasomotor, Vaginal Symptoms of Menopause Benzinga

08:30AM EDT Dar Bioscience Announces Positive Topline Results From Phase 1 Trial Of DARE-HRT1 RTTNews

08:06AM EDT Dar Bioscience Announces Phase 1 Results For DARE-HRT1; Says Drug 'demonstrated the ability to deliver two different active pharmaceutical ingredients' Over 28-Day Period Benzinga

08:00AM EDT Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause GlobeNewswire Inc

Jun 4, 2021

08:00AM EDT DarBioscience, Inc.(NASDAQ: DARE), a leader in womens health innovation, today announced that it has been selected to deliver a company presentation at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021. GlobeNewswire Inc

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

08:05AM EDT Dare Bioscience Q1 EPS $(0.16) Beats $(0.22) Estimate Benzinga

08:00AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today reported financial results for the quarter ended March 31, 2021 and provided a company update. GlobeNewswire Inc

04:15AM EDT Earnings Scheduled For May 13, 2021 Benzinga

May 6, 2021

08:00AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that it will host a conference call and live webcast at4:30 p.m. Eastern Timeon Thursday, May 13, 2021, to review its financial results for the quarter ended March 31, 2021 and to provide a Company update. GlobeNewswire Inc

Apr 27, 2021

08:05AM EDT Dar Bioscience Announces Ovaprene Novel Investigational Hormone-Free Contraceptive Poster Presentation At 2021 Annual Clinical And Scientific Meeting Of American College Of Obstetricians And Gynecologists Benzinga

08:00AM EDT Dar Bioscience Announces Ovaprene, a Novel GlobeNewswire Inc

Apr 26, 2021

08:04AM EDT Dare Biosciences Highlights Presentation Of DARE-BVFREE Phase 3 Trial Results At Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists Apr. 30-May 2 Benzinga

08:00AM EDT Dar Bioscience Announces the Presentation of GlobeNewswire Inc

Apr 19, 2021

08:00AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. GlobeNewswire Inc

Mar 30, 2021

08:22AM EDT Dare Bioscience: Q4 Earnings Insights Benzinga

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

08:00AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today reported financial results for the year ended December 31, 2020 and provided a company update. GlobeNewswire Inc

04:04AM EDT Earnings Scheduled For March 30, 2021 Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 24, 2021

08:26AM EDT Dar Bioscience Begins Phase 2b RESPOND Study Of Sildenafil Cream, 3.6% In Women With Female Sexual Arousal Disorder RTTNews

08:06AM EDT Dar Bioscience Announces Initiation Of Phase 2b RESPOND Study Of Sildenafil Cream, 3.6% In Women With Female Sexual Arousal Disorder Benzinga

08:00AM EDT DarBioscience, Inc.(NASDAQ:DARE), a leader in womens health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the initiation of the Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% for the treatment of female sexual arousal disorder (FSAD). GlobeNewswire Inc

Mar 23, 2021

08:00AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that it will host a conference call and live webcast at4:30 p.m. Eastern Timeon Tuesday, March 30, 2021, to review its financial results for the year ended December 31, 2020 and to provide a Company update. GlobeNewswire Inc

Mar 22, 2021

08:03AM EDT Dar Bioscience Completes Recruitment in Phase 1 Clinical Trial of DARE-HRT1, Novel Intravaginal Ring Designed to Deliver Non-Oral, Bio-identical Hormone Therapy for the Treatment of Vasomotor Symptoms and Genitourinary Syndrome Associated with Menopause Benzinga

08:00AM EDT DarBioscience, Inc.(NASDAQ:DARE), a leader in womens health innovation, today announced completion of patient recruitment in its Phase 1 clinical trial of DARE-HRT1 being conducted through its wholly owned subsidiary in Australia. GlobeNewswire Inc

Mar 10, 2021

08:00AM EST DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming virtual conferences: GlobeNewswire Inc

Mar 8, 2021

08:46AM EST DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a panel discussion titled Womens Health Companies Blazing the Trail at the 33rd Annual Roth Conference that will take place virtually March 15 17, 2021. GlobeNewswire Inc

Mar 2, 2021

08:00AM EST DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference that will take place virtually March 9 10, 2021. GlobeNewswire Inc

Feb 25, 2021

08:00AM EST Dar Bioscience to Participate in Maxim GlobeNewswire Inc

Feb 16, 2021

08:00AM EST Dar Bioscience to Participate at the GlobeNewswire Inc

Feb 9, 2021

08:00AM EST DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the BIO CEO & Investor Digital Conference that will take place virtually February 16 18, 2021. GlobeNewswire Inc

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

10:19AM EST Mid-Morning Market Update: Markets Open Higher; Morgan Stanley Beats Q4 Expectations Benzinga

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 7, 2021

04:16PM EST Dare Bioscience Inc Files For Offer And Sale Of Up To 6.4M Shares Of Common Stock By Lincoln Park Capital Fund Benzinga

Jan 5, 2021

08:00AM EST DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT 2021Virtual Conference to be held January 11-14, 2021. GlobeNewswire Inc

Dec 22, 2020

04:14PM EST Dare Bioscience Files Prospectus Relating To Offer, Sale Or Other Disposition Of Up To 7.1M Shares By Selling Lincoln Park Stockholders Benzinga

Dec 18, 2020

10:10AM EST Benzinga's Top Upgrades, Downgrades For December 18, 2020 Benzinga

08:08AM EST HC Wainwright & Co. Initiates Coverage On Dare Bioscience with Buy Rating, Announces Price Target of $5 Benzinga

Dec 7, 2020

08:16AM EST Dar Bioscience Phase 3 Trial Of DARE-BV1 Trial Met Its Primary Endpoint RTTNews

08:04AM EST Dar Bioscience Announces Topline Results From DARE-BVFREE Phase 3 Trial Of DARE-BV1 In Patients Diagnosed With Bacterial Vaginosis; DARE-BV1 Met Primary Endpoint And All Pre-specified Secondary Efficacy Endpoints Benzinga

08:00AM EST DARE-BV1 met the primary endpoint of the study and all pre-specified secondary efficacy endpoints; demonstrated significantly greater clinical cure rates compared to placebo GlobeNewswire Inc

Nov 12, 2020

08:17AM EST Recap: Dare Bioscience Q3 Earnings Benzinga

08:05AM EST Dare Bioscience Q3 EPS $(0.24) Misses $(0.17) Estimate Benzinga

08:00AM EST DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today reported financial results for the third quarter ended September 30, 2020 and provided a company update. GlobeNewswire Inc

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

04:18AM EST Earnings Scheduled For November 12, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Oct 7, 2020

08:00AM EDT DarBioscience, Inc.(NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the 2020 BIO Investor Forum, which will be held in a digital format October 13-15, 2020. The company presentation will be available on demand during the virtual event for all registered attendees. GlobeNewswire Inc

Sep 21, 2020

08:05AM EDT Dar Bioscience Receives $900K Under Current Grant Supplement Award For Continued Development Of Its User-Controlled, Long Acting Reversible Contraceptive Benzinga

08:00AM EDT Dar Bioscience Receives $0.9 million Under the Current GlobeNewswire Inc

Sep 8, 2020

08:01AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, Dars President and CEO, will participate in two upcoming virtual conferences: GlobeNewswire Inc

Sep 1, 2020

08:19AM EDT Dar Bioscience And Avomeen Form Partnership To 'Accelerate the Development of Dar's Novel Pipeline of Women's Health Programs' Benzinga

08:13AM EDT Dar Bioscience And Avomeen Sign Strategic RTTNews

08:04AM EDT Dar Bioscience and Avomeen Form Strategic Partnership GlobeNewswire Inc

Aug 20, 2020

08:10AM EDT Dar Bioscience Announces Publication Of DARE-BV1 Proof Of Concept Study For Bacterial Vaginosis RTTNews

08:02AM EDT Dar Bioscience Announces Publication Of DARE-BV1 Proof Of Concept Study For The Treatment Of Bacterial Vaginosis Benzinga

08:00AM EDT Dar Bioscience Announces Publication of DARE-BV1 Proof GlobeNewswire Inc

Aug 19, 2020

08:09AM EDT Dar Bioscience Announces Funding Award Of $2.3M From National Institute Of Health Benzinga

08:00AM EDT Dar Bioscience Announces Funding Award Notice from the GlobeNewswire Inc

Aug 12, 2020

08:10AM EDT Dare Bioscience Q2 EPS $(0.27) Misses $(0.15) Estimate Benzinga

08:00AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today reported financial results for the second quarter ended June 30, 2020 and provided a company update. GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 12, 2020 Benzinga

Aug 6, 2020

08:00AM EDT DarBioscience, Inc.(NASDAQ: DARE), a leader in womens health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during Maxim Groups M-Vest Virtual Conference Series: Leading Innovators in Womens Health, beginning at 10:00 a.m. Eastern Time on Thursday, August 13, 2020. GlobeNewswire Inc

Aug 5, 2020

08:00AM EDT DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced that it will host a conference call and live webcast at4:30 p.m. Eastern TimeonWednesday, August 12, 2020, to review its financial results for the quarter ended June 30, 2020 and to provide a Company update. GlobeNewswire Inc

Jul 27, 2020

08:23AM EDT Dar Bioscience Begins Phase 1 Clinical Trial RTTNews

08:07AM EDT Dar Bioscience Announces Initiation Of Phase 1 Clinical Trial Of DARE-HRT1, A Novel Intravaginal Ring Designed To Deliver Non-Oral, Bio-Identical Hormone Therapy For Treatment Of Menopausal Symptoms Benzinga

08:01AM EDT Dar Bioscience, Inc. (NASDAQ:DARE), a leader in womens health innovation, today announced the initiation of a Phase 1 clinical trial of DARE-HRT1. GlobeNewswire Inc